Wells Fargo has upgraded Johnson & Johnson (JNJ) to Overweight from Equal-Weight, signaling a more optimistic outlook on the company's future. This change, effective October 2, 2025, comes as Johnson & Johnson continues to navigate the complex landscape of the pharmaceuticals industry, which includes its extensive portfolio in Innovative Medicine and MedTech segments.
As of the latest financial snapshot, Johnson & Johnson boasts a market capitalization of $486.4 billion and a price-to-earnings ratio of 19.37. The company reported earnings per share of $10.36 and a dividend yield of 256.8%. Upcoming earnings reports are anticipated on April 13, 2026, with an estimated EPS of $2.79, and on July 14, 2026, with an estimated EPS of $2.93.
The upgrade underscores improved analyst sentiment, potentially reflecting stronger fundamentals or enhanced confidence in the company's strategic initiatives. However, it's important to remember that analyst ratings are based on research and financial models, which may not always align with actual performance.
Johnson & Johnson, headquartered in New Brunswick, New Jersey, is a holding company engaged in the research, development, manufacture, and sale of healthcare products. The company employs approximately 138,100 full-time workers and operates in various therapeutic areas, including immunology, oncology, and cardiovascular health.
As of November 1, 2025, the analyst consensus on Johnson & Johnson remains a Buy, with a distribution of 6 Strong Buy, 12 Buy, and 13 Hold ratings among 31 analysts. This reflects a generally positive outlook despite the variability in analyst opinions that can arise from new data.
Such decisions reflect the dynamic nature of market analysis and the importance of considering multiple factors when making investment choices.